

Non-Promotional Medical Satellite Symposium

BTK Inhibitors in MS:

Defining the Next Chapter – From Emerging Evidence to Phase III Insights

Thursday, December 3 I 15:15–16:15
Al Baraha 1 (Lower Level), Events Centre – InterContinental Dubai Festival City

NOVARTIS

REGISTER TODAY
Limited seats available

Chairperson



Prof. Bassem I. Yamout

Professor of Neurology, Director Neurology Institute
American University of Beirut & Harley Street Medical Center
Abu Dhabi, United Arab Emirates

Speakers



Prof. Celia Oreja-Guevara

Consultant Neurologist, Professor of Neurology, Vice Chair of Neurology Hospital Universitario ClÃnico San Carlos, Universidad Complutense de Madrid
Madrid, Spain



Prof. Heinz Wiendl

Professor & Director of the Department of Neurology and Neurophysiology
University Hospital Freiburg
Freiburg, Germany

Agenda

Topic	Speaker	Duration
Welcome and Setting the Stage: BTK inhibition in the evolving MS landscape	**Prof. Bassem Yamout –** President, MENACTRIMS	**05 min**
Understanding BTK Inhibition Across the MS Continuum: Potential, differences between BTK inhibitors, mechanisms, selectivity, and emerging evidence	**Prof. Celia Oreja-Guevara**	**20 min**
From Emerging Evidence to Phase III Results: Efficacy and Safety of Remibrutinib vs. Teriflunomide in Relapsing Multiple Sclerosis: Results of the Phase III REMODEL-1/-2 Trials	**Prof. Heinz Wiendl (Virtual)**	**20 min**
Expert Discussion and Q&A	**All Faculty**	**15 min**

NOV/2026/ FA-50002840

* *Novartis hereby invites you to this event without having obtained or without aiming at obtaining anything in return from your part. By accepting this invitation, the invitee confirms that his/her participation in this educational and informational event does not violate any local laws and/or regulations, and it does not create any conflict of interest with his/her job. The invitee will disclose this engagement and related expenses of coverage to any person, authority or committee, as required. Novartis shall in no way be held liable for any failure to secure such disclosure/approval. As per the Middle East and Africa Code of pharmaceutical promotional practices, spouses, relatives or other guests in relation with the healthcare professional cannot be invited or included in any promotional, professional or scientific event including dinners and other Novartis organized events. For virtual meetings, HCPs are advised not to share the invite onwards*
* *For adverse event reporting to UAE EDE, please contact pv@ede.gov.ae*
* *For any adverse events in Abu Dhabi, please report it to Pharmacovigilance & Drugs Education PVE@doh.gov.ae*
* *To report adverse events to Novartis, email to ae.safetyreports@novartis.com or report online by visiting https://www.novartis.com/report*
* *This material may include data / information on investigational uses of compounds / drugs that have not been approved by regulatory authorities.*
* *Novartis Middle East FZE (Representative Office) Limitless Building, 5th floor, Jumeirah Village Triangle P.O. Box 23510, Dubai, United Arab Emirates www.novartis.com*